Insider Selling: Bausch Health Companies Inc. (TSE:BHC) Senior Officer Sells C$112,087.40 in Stock

Bausch Health Companies Inc. (TSE:BHC) Senior Officer Seana Lynne Carson sold 13,370 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40.

Bausch Health Companies Price Performance

TSE:BHC opened at C$8.67 on Thursday. The business’s 50-day simple moving average is C$8.69 and its two-hundred day simple moving average is C$10.25. Bausch Health Companies Inc. has a 52 week low of C$5.45 and a 52 week high of C$15.43. The stock has a market cap of C$3.18 billion, a PE ratio of -4.98, a P/E/G ratio of 0.21 and a beta of 0.75. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of 7,583.76.

Bausch Health Companies (TSE:BHC) last issued its earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The company had revenue of C$3.29 billion for the quarter, compared to the consensus estimate of C$3.20 billion. As a group, analysts forecast that Bausch Health Companies Inc. will post 4.9320988 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Raymond James upgraded Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 10th.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.